Kymera reports Phase 1 data for STAT3 degrader KT-333: one PR in CTCL, no DLTs

Kymera Therapeutics, Inc.

21 patients enrolled through dose level 5; 12 evaluable for disease assessment.
One partial response in cutaneous T-cell lymphoma (CTCL) at DL2; stable disease in 3 solid tumor patients (DL3/4).
No dose-limiting toxicities or serious adverse events; most AEs Grade 1/2 (constipation, fatigue, nausea, anemia).
Dose-dependent, sustained STAT3 degradation in PBMCs at DL3+ at levels linked to preclinical anti-tumor activity.
Updated data to be presented at ASH 2023 on December 10.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.